These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27694421)

  • 1. Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
    McNaughton A; Blackmore T; McNaughton H
    Eur Respir J; 2016 Oct; 48(4):1256-1259. PubMed ID: 27694421
    [No Abstract]   [Full Text] [Related]  

  • 2. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection?
    Lobato MN; Jereb JA; Castro KG
    Pediatrics; 2009 Mar; 123(3):902-3. PubMed ID: 19255018
    [No Abstract]   [Full Text] [Related]  

  • 4. TB Alliance regimen development for multidrug-resistant tuberculosis.
    Murray S; Mendel C; Spigelman M
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When students become patients: TB disease among medical undergraduates in Cape Town, South Africa.
    Van der Westhuizen HM; Dramowski A
    S Afr Med J; 2017 May; 107(6):475-479. PubMed ID: 28604316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Marks SM; Mase SR; Morris SB
    Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
    Caminero JA; Sotgiu G; Zumla A; Migliori GB
    Lancet Infect Dis; 2010 Sep; 10(9):621-9. PubMed ID: 20797644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
    Fisher M; Tomlinson DR; Coker RJ
    Int J STD AIDS; 1996 Jul; 7(4):244-9; quiz 249-51. PubMed ID: 8876354
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extra-pulmonary primary multidrug-resistant tubercular lymphadenitis in an HIV negative patient.
    Kant S; Saheer S; Hassan G; Parengal J
    BMJ Case Rep; 2012 May; 2012():. PubMed ID: 22605844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
    Kononets AS
    Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
    Alame-Emane AK; Xu P; Pierre-Audigier C; Cadet-Daniel V; Shen X; Sraouia M; Siawaya JF; Takiff H; Gao Q; Gicquel B
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):679-84. PubMed ID: 25946359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A breathtaking response to tuberculosis therapy.
    Boerrigter BG; van Sandwijk MS; van den Berk GE
    Neth J Med; 2013 Jun; 71(5):258-62. PubMed ID: 23799314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.